# Omalizumab

## Xolair inj 150mg/mL

##### 臨採

| TAH Drug Code      | [IXOLA](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IXOLA)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Allergy to food, IgE-mediated allergic reaction (Type 1) Allergy to latex Chronic rhinosinusitis with nasal polyps, Inadequate response to nasal corticosteroids; Adjunct Idiopathic urticaria, chronic, H1 antihistamine-refractory IgE-mediated allergic asthma, Not controlled by inhaled corticosteroids                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | Allergy to food, IgE-mediated allergic reaction (Type 1)/Chronic rhinosinusitis with nasal polyps, Inadequate response to nasal corticosteroids; Adjunct/IgE-mediated allergic asthma, Not controlled by inhaled corticosteroids: The appropriate dose and frequency of Xolair is determined by baseline IgE (IU/ml), measured before the start of treatment, and body weight (kg). Prior to administration of the initial dose, patients should have their IgE level determined by any commercial serum total IgE assay for their dose assignment. Based on these measurements, 75 to 600 mg of Xolair every 2 to 4 weeks may be needed for each administration. Allergy to latex: 150 to 750 mg/month subQ, administered either as a divided dose every 2 weeks or as single dose every 4 weeks. Select dosage based on body weight (kg) and serum IgE levels (international units/mL). Appropriate duration of therapy has not been established, but 32 weeks is suggested (off-label dosage). Idiopathic urticaria, chronic, H1 antihistamine-refractory: 150 or 300 mg subQ every 4 weeks. Appropriate duration of therapy has not been established; periodically reassess the need for continued therapy. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Contraindications  | Severe hypersensitivity reaction to omalizumab or any ingredient of omalizumab subcutaneous injection products                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Adverse Effects    | Common: Injection site disorder (Allergic asthma, 45%; chronic idiopathic urticaria, 0.6-2.7%; chronic rhinosinusitis, 5.2%; IgE-mediated food allergy, 15.5%), Upper abdominal pain (3% or greater), Viral gastroenteritis (3% or greater), Arthralgia (2.9-8%), Headache (3-15%), Otitis media (3% or greater), Bleeding from nose (3% or greater), Nasopharyngitis (3-9.1%), Sinusitis (Allergic asthma, 16%; chronic idiopathic urticaria, 1.1-4.9%), Streptococcal pharyngitis (3% or greater), Arthropod bite wound (3% or greater), Fever (3-6.4%), Pain (Allergic asthma, 7%). Serious: Myocardial infarction, Unstable angina, Disorder of eosinophil (Rare), Venous thrombosis, Anaphylaxis (0.1%), Cerebrovascular disease, Transient ischemic attack, Pulmonary embolism, Pulmonary hypertension, Cancer (Asthma and other allergic disorders, 0.5%), Helminth infection (Patients at high risk for geohelminthic infections, 53%), Serum sickness caused by drug.                                                                                                                                                                                                                                  |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| More Info          | [UpToDate](https://www.uptodate.com/contents/omalizumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

